General
Preferred name
Siremadlin
Synonyms
NVP-HDM 201 ()
HDM201 ()
HDM-201 ()
NVP-HDM201 ()
SIREMADLIN SUCCINATE ()
Siremadline ()
Siremadlina ()
Hdm 201 ()
NVP-HDM201-BBA ()
HDM201 BBA ()
HDM-201 SUCCINATE ()
HDM201 SUCCINATE ()
P&D ID
PD101146
CAS
1448867-41-1
Tags
available
drug candidate
Drug indication
Myelofibrosis
Neoplasm
Solid tumour/cancer
Haematological malignancy
Liposarcoma
Drug Status
investigational
Max Phase
2.0
1.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Siremadlin (NVP-HDM201) is a potent, orally bioavailable and highly specific p53-MDM2 interaction inhibitor.
PRICE
209
DESCRIPTION
Siremadlin (NVP-HDM 201) is a potent, orally bioavailable and highly specific p53-MDM2 interaction inhibitor.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
11
Cayman Chemical Bioactives
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
21
Molecular Weight
554.12
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
5
Aromatic Ring Count
4
cLogP
4.69
TPSA
104.37
Fraction CSP3
0.27
Chiral centers
1.0
Largest ring
6.0
QED
0.34
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
E1/E2/E3 Enzyme
MDM-2/p53
p53-MDM2
Member status
virtual
MOA
p53-HDM2 PPI inhibitor
p53-MDM2 PPI inhibitor
MDM inhibitor
Pathway
Apoptosis
Metabolic Enzyme/Protease
Ubiquitination
Source data
